Prostate-specific antigen testing in black and white men: An analysis of medicare claims from 1991-1998

Urology

Volumn 59, Issue 2, 2002, Pages 251-255

  Etzioni, Ruth ^a,b   Berry, Kristin M ^a,b   Legler, Julie M ^a,b   Shaw, Pamela ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RISK; CANCER SCREENING; CAUCASIAN; CONTROLLED STUDY; ETHNIC GROUP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; NEGRO; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; UNITED STATES;

AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES;

EID: 0036166841     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01516-3     Document Type: Article

References (15)

1. The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the USA
2. Interpreting trends in prostate cancer. Part I. Evidence of the effects of screening in recent prostate cancer incidence, survival and mortality rates
3. Knowledge, beliefs and prior screening behavior among blacks and whites reporting for prostate cancer screening
4. Knowledge, attitudes and screening practices among older men regarding prostate cancer
5. African American men, prostate cancer early detection examination uses, and informed decision-making
6. Barriers to prostate cancer screening in African American men
7. The validity of male patients' self-reports regarding prostate cancer screening
8. Potential for cancer related health services research using a linked Medicare-tumor registry database
9. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening
10. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?
11. Nonparametric estimation from incomplete observations
12. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute
13. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer; European randomized study of screening for prostate cancer, Rotterdam